Australian T1D National Screening Pilot
University of Sydney / Australian Type 1 Diabetes Clinical Research Network / Breakthrough T1D, with Australian Government support
The national-screening groundwork is funded; the national service is not.
What it is
Australia's first head-to-head screening pilot has closed, but the programme has moved into a funded second phase. A new 15-month school study will screen 7,500 children aged 4-12 for islet autoantibodies, alongside three-year work to build accredited high-throughput laboratories, data systems, and a national care pathway. This is nearly A$10 million of screening-readiness research, not yet a government-funded population service.
Editorial review: .
Most recent recorded citation date: 2026-02-25. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Predictive value: Deliberately heterogeneous, because comparing the models is the point: two of the three arms screen genetic risk, which stratifies who is more likely to develop autoantibodies rather than identifying who has T1D, and only the third measures islet autoantibodies directly. The genetic arms add autoantibody testing later (from about 10-11 months) to convert risk into an actual diagnosis of early-stage T1D.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Not an open national service. The first self-registration pilot has closed; the new 7,500-child phase is school-based. Type1Screen remains an available route, now offered beyond relatives.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 62 × 25 + 66 × 25 + 84 × 20 + 82 × 15 + 28 × 15 = 6530; divide by total weight 100. Unrounded weighted result: 65.3.
Deliberately heterogeneous, because comparing the models is the point: two of the three arms screen genetic risk, which stratifies who is more likely to develop autoantibodies rather than identifying who has T1D, and only the third measures islet autoantibodies directly. The genetic arms add autoantibody testing later (from about 10-11 months) to convert risk into an actual diagnosis of early-stage T1D.[1]
Children who screen positive can enter monitoring and education, the route that prevents ketoacidosis at diagnosis. The new programme also explicitly funds a three-year evaluation of care pathways across eight clinical centres, but it remains implementation research rather than a clinical outcomes trial or health service.[4]
Explicitly general-population rather than relatives-only. The next phase will screen 7,500 schoolchildren aged 4-12 and includes partnerships with Indigenous and culturally and linguistically diverse communities.[4]
Two of the three models add nothing invasive: they reuse the newborn heel-prick blood spot already taken at birth, or a saliva sample from an infant. The third is a capillary finger-prick dried blood spot. Only screen-positive children need further testing.[1]
Nearly A$10 million now funds the evidence and infrastructure work, but this pilot is not a universal screening service. Separate Type1Screen testing is now free for anyone in Australia over age 1. The new phase is school-based research, not universal clinical access.[4]
The full picture
The Australian Type 1 Diabetes National Screening Pilot asked a question most screening programmes skip: not whether to screen children for type 1 diabetes (T1D), but how. Led from the University of Sydney through the Australian Type 1 Diabetes Clinical Research Network and funded by JDRF (now Breakthrough T1D), it ran three different general-population screening models against each other in the same country at the same time, so that a future national programme could be built on evidence rather than preference.13
The three models
Every model is aimed at the general population — any child, no family history required — because most people who develop T1D have no relative with it.1
- Newborn genetic screening. A genetic risk score is calculated from the dried blood spot already collected at the newborn heel prick, so no extra sample is taken. Children at higher genetic risk are then offered islet-autoantibody testing from around 11 months of age.1
- Infant saliva genetic screening. A genetic risk score from a saliva sample collected at 6-12 months, with autoantibody testing from around 10 months for those at higher risk.1
- Direct autoantibody screening. A capillary dried blood spot at age 2, 6 or 10, measuring islet autoantibodies straight away — no genetic step.1
The distinction matters. A genetic risk score says a child is more likely to develop the autoimmunity that leads to T1D; islet autoantibodies say the autoimmune process has actually begun. The genetic arms are therefore a funnel, narrowing who gets antibody-tested and when, while the third arm skips the funnel and tests directly.
Size and what it measured
The pilot aimed to enrol up to 3,000 children per model — up to about 9,000 in total — in at least two Australian states per cohort. Its primary outcome was screening uptake: what proportion of families offered each model actually took it up. Feasibility, acceptability and cost-effectiveness sit alongside it.1 That is a policy question dressed as a study, and it is the honest reason this record scores modestly on actionability: the pilot was built to tell a government which screening model a country would actually use, not to prove that screening changes an individual child's outcome.
Where it stands now
The protocol describes a pilot period of July 2022 to June 2024, and the study's own website states that it has closed for new self-registrations.12 So this is not something a family can join today. As of this review we found no published results.
The programme did not stop there. On 25 February 2026, Breakthrough T1D announced nearly A$10 million for three linked screening-readiness projects.4 The University of Sydney team is leading a new 15-month school-screening phase that will test 7,500 children aged 4-12 for islet autoantibodies, with explicit partnerships for Indigenous and culturally and linguistically diverse communities.
Two parallel three-year projects address the parts a test alone cannot solve. One is building accredited high-throughput autoantibody testing, laboratory capacity, and national data systems. The other will compare early-stage T1D care across eight clinical centres, including monitoring pathways and links to disease-modifying trials.4 That is the health-system work required before screening can become a durable service rather than a sample-collection campaign.
The screening an Australian family can request today remains Type1Screen, which now offers free testing to anyone in Australia over age 1, irrespective of family history. A voluntary screening offer is different from a universal pathway embedded in routine care.
How to read this record
We list the programme as pipeline, not available, deliberately. Nearly A$10 million in research funding is not a government decision to provide screening to every child. The next phase is school-based research, and the laboratory and care pathways are still being built. What remains pending is a sustainable, government-funded national service and an implementation date; neither has been announced.4
Coming soon
ETA · The 15-month school-screening phase and two parallel three-year infrastructure projects are intended to support a future government-funded programme. No national service or government implementation date has been announced.
- →A 15-month second-phase pilot screening 7,500 children aged 4-12 at school for islet autoantibodies
- →Three-year work to accredit high-throughput autoantibody testing, expand laboratory/data capacity, and evaluate early-stage T1D care at eight centres
- →Government decision on a sustainable national general-population screening service; no implementation date has been announced
Sources
- [1]Protocol for the Australian Type 1 Diabetes National Screening Pilot: Assessing the feasibility and acceptability of three general population screening models in children · Peer-reviewed study · 2024-08-11 — Bell KJ et al., Diabetic Medicine 41(11):e15419. Sets out the three screening models, up to 3,000 children per cohort across at least two states each, screening uptake as the primary outcome, and a pilot period of July 2022 to June 2024.
Bell KJ, et al. Protocol for the Australian Type 1 Diabetes National Screening Pilot: Assessing the feasibility and acceptability of three general population screening models in children. Diabetic Medicine 41(11):e15419 (2024).
- [2]Type 1 Diabetes National Screening Pilot (official study site) · Trial registry — States that the pilot has closed for new self-registrations.
Type 1 Diabetes National Screening Pilot (official study site). kidsdiabetesscreen.com.au (accessed 2026).
- [3]Australian Type 1 Diabetes National Screening Pilot: advancing the evidence base towards national public health implementation · Open-source community — Funder's grant record. We do not publish a funding figure here because we could not verify one against a primary source.
Breakthrough T1D. Australian Type 1 Diabetes National Screening Pilot: advancing the evidence base towards national public health implementation (grant record).
- [4]National T1D screening supported with nearly $10m from Breakthrough T1D · Open-source community · 2026-02-25 — Official funder announcement: a 15-month 7,500-child school-screening phase plus two three-year national laboratory/infrastructure and care-model projects. It says the work is intended to support a future government programme, not that one has been approved.
Breakthrough T1D. National T1D screening supported with nearly $10m from Breakthrough T1D (25 February 2026).